{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T04:14:14Z","timestamp":1783311254162,"version":"3.54.6"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100016086","name":"Key Laboratory in Science and Technology Development Project of Suzhou","doi-asserted-by":"publisher","award":["SZXK202106"],"award-info":[{"award-number":["SZXK202106"]}],"id":[{"id":"10.13039\/100016086","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016086","name":"Key Laboratory in Science and Technology Development Project of Suzhou","doi-asserted-by":"publisher","award":["SS202067"],"award-info":[{"award-number":["SS202067"]}],"id":[{"id":"10.13039\/100016086","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    This retrospective study presents a 10-year-old male with multi-systemic venous thromboembolism (VTE) secondary to COVID-19, including right ventricular thrombus(40\u00a0mm \u00d7 18\u00a0mm), bilateral iliac vein thrombosis, pulmonary embolism, and renal vein thrombosis. The child presented with fever, abdominal pain, and elevated inflammatory markers (CRP 222.72\u00a0mg\/L, WBC 22.41\u2009\u00d7\u200910\n                    <jats:sup>\u2079<\/jats:sup>\n                    \/L). Imaging confirmed extensive thrombi in the right ventricle, pulmonary arteries, and lower extremities. Anticoagulation with rivaroxaban (10\u00a0mg QD) was initiated alongside anti-infective and anti-inflammatory therapies. Over a 3-year follow-up, thrombus burden significantly regressed, with D-dimer decreasing from 73 430\u00a0\u00b5g\/L to 290\u00a0\u00b5g\/L, and no recurrence or bleeding complications were observed. Coagulation parameters (PT, APTT) stabilized within therapeutic ranges. This case suggests the efficacy and safety of rivaroxaban in long-term management of multi-system VTE in pediatric patient, especially in cases of COVID-19-associated hypercoagulability. The primary clinical outcomes were the resolution of thrombus burden as evidenced by imaging and the absence of bleeding complications or recurrence during the follow-up period. The findings align with emerging evidence supporting direct oral anticoagulants (DOACs) in children, emphasizing individualized dosing and long-term management. Further studies are warranted to validate DOACs\u2019 role in pediatric thrombosis, especially in the context of viral infections.\n                  <\/jats:p>","DOI":"10.1186\/s13023-026-04382-7","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T13:43:24Z","timestamp":1778334204000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rare pediatric multi-system thrombosis post-COVID-19: a three-year follow-up case report and narrative review on rivaroxaban for long-term management"],"prefix":"10.1186","volume":"21","author":[{"given":"Shiyi","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaozhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruyue","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0590-9359","authenticated-orcid":false,"given":"Ningxun","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"10","key":"4382_CR1","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1182\/bloodadvances.2024015328","volume":"9","author":"P Monagle","year":"2025","unstructured":"Monagle P, Azzam M, Bercovitz R, et al. American Society of Hematology\/International Society on Thrombosis and Haemostasis 2024 updated guidelines for treatment of venous thromboembolism in pediatric patients. Blood Adv. 2025;9(10):2587\u2013636.","journal-title":"Blood Adv"},{"issue":"5","key":"4382_CR2","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1111\/jth.14739","volume":"18","author":"AA Sharathkumar","year":"2020","unstructured":"Sharathkumar AA, Biss T, Kulkarni K, et al. Epidemiology and outcomes of clinically unsuspected venous thromboembolism in children: A systematic review. J Thromb Haemostasis: JTH. 2020;18(5):1100\u201312.","journal-title":"J Thromb Haemostasis: JTH"},{"issue":"12","key":"4382_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/jamasurg.2013.3558","volume":"148","author":"KJ Van Arendonk","year":"2013","unstructured":"Van Arendonk KJ, Schneider EB, Haider AH, et al. Venous thromboembolism after trauma: when do children become adults? JAMA Surg. 2013;148(12):1123\u201330.","journal-title":"JAMA Surg"},{"key":"4382_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.trsl.2020.05.006","volume":"225","author":"MA Bray","year":"2020","unstructured":"Bray MA, Sartain SE, Gollamudi J, et al. Microvascular thrombosis: experimental and clinical implications. Translational Research: J Lab Clin Med. 2020;225:105\u201330.","journal-title":"Translational Research: J Lab Clin Med"},{"key":"4382_CR5","doi-asserted-by":"publisher","first-page":"1507167","DOI":"10.3389\/fimmu.2025.1507167","volume":"16","author":"I Serrano-Gonzalo","year":"2025","unstructured":"Serrano-Gonzalo I, Men\u00e9ndez-Jandula B, Franco-Garc\u00eda E, et al. Neutrophil extracellular traps and macrophage activation contibute to thrombosis and post-covid syndrome in SARS-CoV-2 infection. Front Immunol. 2025;16:1507167.","journal-title":"Front Immunol"},{"key":"4382_CR6","doi-asserted-by":"crossref","unstructured":"Scimeca G, Krishnathasan D, Rashedi S, et al. Predictors of venous thromboembolic events in hospitalized patients with COVID-19. J Thromb Thrombolysis. 2025.","DOI":"10.1007\/s11239-025-03078-2"},{"issue":"2","key":"4382_CR7","doi-asserted-by":"publisher","first-page":"e30112","DOI":"10.1002\/pbc.30112","volume":"70","author":"A Yan","year":"2023","unstructured":"Yan A, Parsons C, Caplan G, et al. Improving guideline-concordant thromboprophylaxis prescribing for children admitted to hospital with COVID-19. Pediatr Blood Cancer. 2023;70(2):e30112.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"4382_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.jinf.2020.06.008","volume":"81","author":"E Grifoni","year":"2020","unstructured":"Grifoni E, Valoriani A, Cei F, et al. Interleukin-6 as prognosticator in patients with COVID-19. J Infect. 2020;81(3):452\u201382.","journal-title":"J Infect"},{"issue":"1","key":"4382_CR9","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","volume":"9","author":"H Han","year":"2020","unstructured":"Han H, Ma Q, Li C, et al. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors. Emerg Microbes Infections. 2020;9(1):1123\u201330.","journal-title":"Emerg Microbes Infections"},{"key":"4382_CR10","doi-asserted-by":"publisher","first-page":"626235","DOI":"10.3389\/fimmu.2021.626235","volume":"12","author":"A Ma","year":"2021","unstructured":"Ma A, Zhang L, Ye X, et al. High Levels of Circulating IL-8 and Soluble IL-2R Are Associated With Prolonged Illness in Patients With Severe COVID-19. Front Immunol. 2021;12:626235.","journal-title":"Front Immunol"},{"key":"4382_CR11","doi-asserted-by":"crossref","unstructured":"Roy TK, Secomb TW. Effects of impaired microvascular flow regulation on metabolism-perfusion matching and organ function. Microcirculation (New York, N.Y.: 1994). 2021;28(3):e12673.","DOI":"10.1111\/micc.12673"},{"key":"4382_CR12","doi-asserted-by":"crossref","unstructured":"Braquet P, Hosford D, Braquet M, et al. Role of cytokines and platelet-activating factor in microvascular immune injury. Int Arch Allergy Appl Immunol. 1989;88:1\u20132.","DOI":"10.1159\/000234755"},{"key":"4382_CR13","doi-asserted-by":"publisher","first-page":"p2755246","DOI":"10.1155\/2022\/2755246","volume":"2022","author":"Y Chang","year":"2022","unstructured":"Chang Y, Bai M, You Q. Associations between Serum Interleukins (IL-1\u03b2, IL-2, IL-4, IL-6, IL-8, and IL-10) and Disease Severity of COVID-19: A Systematic Review and Meta-Analysis. Biomed Res Int. 2022;2022:p2755246.","journal-title":"Biomed Res Int"},{"issue":"22","key":"4382_CR14","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1182\/bloodadvances.2018024786","volume":"2","author":"P Monagle","year":"2018","unstructured":"Monagle P, Cuello CA, Augustine C, et al. American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism. Blood Adv. 2018;2(22):3292\u2013316.","journal-title":"Blood Adv"},{"issue":"5","key":"4382_CR15","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/pan.13355","volume":"28","author":"J Morgan","year":"2018","unstructured":"Morgan J, Checketts M, Arana A, et al. Prevention of perioperative venous thromboembolism in pediatric patients: Guidelines from the Association of Paediatric Anaesthetists of Great Britain and Ireland (APAGBI). Paediatr Anaesth. 2018;28(5):382\u201391.","journal-title":"Paediatr Anaesth"},{"issue":"4","key":"4382_CR16","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1016\/j.chest.2021.07.025","volume":"160","author":"AS Go","year":"2021","unstructured":"Go AS, Reynolds K, Tabada GH, et al. COVID-19 and Risk of VTE in Ethnically Diverse Populations. Chest. 2021;160(4):1459\u201370.","journal-title":"Chest"},{"issue":"10229","key":"4382_CR17","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London England). 2020;395(10229):1054\u201362.","journal-title":"Lancet (London England)"},{"key":"4382_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ijlh.12665","volume":"39","author":"LA Linkins","year":"2017","unstructured":"Linkins LA, Takach Lapner S. Review of D-dimer testing: Good, Bad, and Ugly. Int J Lab Hematol. 2017;39:1.","journal-title":"Int J Lab Hematol"},{"issue":"6","key":"4382_CR19","doi-asserted-by":"publisher","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Kreuziger LB, et al. Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. Chest. 2021;160(6):e545\u2013608.","journal-title":"Chest"},{"issue":"4","key":"4382_CR20","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1365-2141.2005.05652.x","volume":"130","author":"N Steeghs","year":"2005","unstructured":"Steeghs N, Goekoop RJ, Niessen RWLM, et al. C-reactive protein and D-dimer with clinical probability score in the exclusion of pulmonary embolism. Br J Haematol. 2005;130(4):614\u20139.","journal-title":"Br J Haematol"},{"key":"4382_CR21","doi-asserted-by":"crossref","unstructured":"Wen Y-H, Zhao H-L, Wu S-Y, et al. CircSARS-CV2-N1368 from SARS-CoV-2 impairs endothelial cell function through the upregulation of ATF7 to activate TLR4\/NF-\u03baB\/ROS signaling. Acta Pharmacol Sin. 2025.","DOI":"10.1038\/s41401-025-01516-8"},{"issue":"11","key":"4382_CR22","doi-asserted-by":"publisher","first-page":"e276","DOI":"10.1016\/S1473-3099(20)30651-4","volume":"20","author":"L Jiang","year":"2020","unstructured":"Jiang L, Tang K, Levin M, et al. COVID-19 and multisystem inflammatory syndrome in children and adolescents. Lancet Infect Dis. 2020;20(11):e276\u201388.","journal-title":"Lancet Infect Dis"},{"key":"4382_CR23","unstructured":"Centers for Disease Control Health Care Providers. Clinical Overview of Multisystem Inflammatory Syndrome in Children[EB\/OL]. December 16, 2025. https:\/\/www.cdc.gov\/mis\/hcp\/clinical-overview\/index.html."},{"key":"4382_CR24","unstructured":"World Health Organization. Multisystem inflammatory syndrome in children and adolescents with COVID-19[EB\/OL]. 15 May 2020. https:\/\/www.who.int\/publications\/i\/item\/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19."},{"issue":"9","key":"4382_CR25","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1016\/j.jtha.2023.05.020","volume":"21","author":"R Kumar","year":"2023","unstructured":"Kumar R, Rivkin MJ, Raffini L. Thrombotic complications in children with Coronavirus disease 2019 and Multisystem Inflammatory Syndrome of Childhood. J Thromb Haemostasis: JTH. 2023;21(9):2313\u201326.","journal-title":"J Thromb Haemostasis: JTH"},{"issue":"10","key":"4382_CR26","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2024.12708","volume":"332","author":"JD Douketis","year":"2024","unstructured":"Douketis JD, Spyropoulos AC. Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review. JAMA. 2024;332(10):825\u201334.","journal-title":"JAMA"},{"issue":"1","key":"4382_CR27","doi-asserted-by":"publisher","first-page":"e18","DOI":"10.1016\/S2352-3026(19)30219-4","volume":"7","author":"C Male","year":"2020","unstructured":"Male C, Lensing AWA, Palumbo JS, et al. Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial. Lancet Haematol. 2020;7(1):e18\u201327.","journal-title":"Lancet Haematol"},{"issue":"7","key":"4382_CR28","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1111\/jth.14813","volume":"18","author":"G Young","year":"2020","unstructured":"Young G, Lensing AWA, Monagle P, et al. Rivaroxaban for treatment of pediatric venous thromboembolism. An Einstein-Jr phase 3 dose-exposure-response evaluation. J Thromb Haemostasis: JTH. 2020;18(7):1672\u201385.","journal-title":"J Thromb Haemostasis: JTH"},{"issue":"11","key":"4382_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/14779072.2020.1823218","volume":"18","author":"O Cohen","year":"2020","unstructured":"Cohen O, Levy-Mendelovich S, Ageno W. Rivaroxaban for the treatment of venous thromboembolism in pediatric patients. Expert Rev Cardiovasc Ther. 2020;18(11):733\u201341.","journal-title":"Expert Rev Cardiovasc Ther"},{"issue":"24","key":"4382_CR30","doi-asserted-by":"publisher","first-page":"6250","DOI":"10.1182\/bloodadvances.2020003244","volume":"4","author":"P Connor","year":"2020","unstructured":"Connor P, van S\u00e1nchez M, Lensing AWA, et al. Safety and efficacy of rivaroxaban in pediatric cerebral venous thrombosis (EINSTEIN-Jr CVT). Blood Adv. 2020;4(24):6250\u20138.","journal-title":"Blood Adv"},{"issue":"7","key":"4382_CR31","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/08880018.2022.2150797","volume":"40","author":"M-C Pelland-Marcotte","year":"2023","unstructured":"Pelland-Marcotte M-C, Tole S, Bouhelier E, et al. Rivaroxaban for Management of Venous Thromboembolism in Pediatric Nephrotic Syndrome; a Case Report and Review of Literature. Pediatr Hematol Oncol. 2023;40(7):688\u201395.","journal-title":"Pediatr Hematol Oncol"},{"key":"4382_CR32","doi-asserted-by":"publisher","first-page":"1005098","DOI":"10.3389\/fped.2022.1005098","volume":"10","author":"M Al-Ghafry","year":"2022","unstructured":"Al-Ghafry M, Sharathkumar A. Direct oral anticoagulants in pediatric venous thromboembolism: Review of approved products rivaroxaban and dabigatran. Front Pead. 2022;10:1005098.","journal-title":"Front Pead"},{"key":"4382_CR33","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.thromres.2022.11.027","volume":"221","author":"E Hassan","year":"2023","unstructured":"Hassan E, Motwani J. Real world experience of efficacy and safety of rivaroxaban in paediatric venous thromboembolism. Thromb Res. 2023;221:92\u20136.","journal-title":"Thromb Res"},{"issue":"6","key":"4382_CR34","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1097\/MPH.0000000000002690","volume":"45","author":"N Montanez","year":"2023","unstructured":"Montanez N, Sexson Tejtel SK, Menon NM. Pediatric Thromboprophylaxis of Large Coronary Artery Aneurysm Using Rivaroxaban. J Pediatr Hematol Oncol. 2023;45(6):356\u20139.","journal-title":"J Pediatr Hematol Oncol"},{"key":"4382_CR35","doi-asserted-by":"publisher","first-page":"109169","DOI":"10.1016\/j.thromres.2024.109169","volume":"243","author":"S McElroy","year":"2024","unstructured":"McElroy S, Cramer E, Amos L. COVID-19 venous thromboembolism prophylaxis guidelines in pediatrics. Thromb Res. 2024;243:109169.","journal-title":"Thromb Res"},{"key":"4382_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12959-018-0186-0","volume":"16","author":"D Kubitza","year":"2018","unstructured":"Kubitza D, Willmann S, Becka M, et al. Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study. Thromb J. 2018;16:31.","journal-title":"Thromb J"},{"key":"4382_CR37","doi-asserted-by":"crossref","unstructured":"Willmann S, Becker C, Burghaus R, et al. Development of a paediatric population-based model of the pharmacokinetics of rivaroxaban. Clin Pharmacokinet. 2014;53(1).","DOI":"10.1007\/s40262-013-0090-5"},{"issue":"10","key":"4382_CR38","doi-asserted-by":"publisher","first-page":"e500","DOI":"10.1016\/S2352-3026(19)30161-9","volume":"6","author":"P Monagle","year":"2019","unstructured":"Monagle P, Lensing AWA, Thelen K, et al. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies. Lancet Haematol. 2019;6(10):e500\u20139.","journal-title":"Lancet Haematol"},{"issue":"9","key":"4382_CR39","doi-asserted-by":"publisher","first-page":"e31140","DOI":"10.1002\/pbc.31140","volume":"71","author":"B Buxton","year":"2024","unstructured":"Buxton B, Elliott K, Schwalm C. Direct oral anticoagulant use in hospitalized pediatric patients: Insights from nationwide data. Pediatr Blood Cancer. 2024;71(9):e31140.","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"4382_CR40","doi-asserted-by":"publisher","first-page":"e31131","DOI":"10.1002\/pbc.31131","volume":"71","author":"S Alqahtani","year":"2024","unstructured":"Alqahtani S, Gibbs KD, Montanez NA, et al. Direct oral anticoagulant therapy in adolescent venous thromboembolism: A systematic review. Pediatr Blood Cancer. 2024;71(9):e31131.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"4382_CR41","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/j.jtha.2024.02.011","volume":"22","author":"S Schulman","year":"2024","unstructured":"Schulman S, Arnold DM, Bradbury CA, et al. 2023 ISTH update of the 2022 ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemostasis: JTH. 2024;22(6):1779\u201397.","journal-title":"J Thromb Haemostasis: JTH"},{"key":"4382_CR42","doi-asserted-by":"crossref","unstructured":"McMichael ABV, Ryerson LM, Ratano D, et al. 2021 ELSO adult and pediatric anticoagulation guidelines. ASAIO J. 2022:68(3):303\u201310.","DOI":"10.1097\/MAT.0000000000001652"},{"key":"4382_CR43","doi-asserted-by":"publisher","first-page":"1519517","DOI":"10.3389\/fped.2025.1519517","volume":"13","author":"Y Wang","year":"2025","unstructured":"Wang Y, Yin Q, Liao J, et al. Addressing challenges in pediatric thrombosis: a comprehensive guideline development. Front Pead. 2025;13:1519517.","journal-title":"Front Pead"},{"key":"4382_CR44","doi-asserted-by":"publisher","first-page":"944743","DOI":"10.3389\/fped.2022.944743","volume":"10","author":"S Trapani","year":"2022","unstructured":"Trapani S, Rubino C, Lasagni D, et al. Thromboembolic complications in children with COVID-19 and MIS-C: A narrative review. Front Pead. 2022;10:944743.","journal-title":"Front Pead"},{"issue":"1","key":"4382_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1089\/gtmb.2017.0152","volume":"22","author":"DA Sychev","year":"2018","unstructured":"Sychev DA, Vardanyan A, Rozhkov A, et al. CYP3A Activity and Rivaroxaban Serum Concentrations in Russian Patients with Deep Vein Thrombosis. Genetic Test Mol Biomarkers. 2018;22(1):51\u20134.","journal-title":"Genetic Test Mol Biomarkers"},{"issue":"6","key":"4382_CR46","doi-asserted-by":"publisher","first-page":"841","DOI":"10.4254\/wjh.v15.i6.841","volume":"15","author":"D Juneja","year":"2023","unstructured":"Juneja D, Nasa P, Jain R. Liver injury from direct oral anticoagulants. World J Hepatol. 2023;15(6):841\u20139.","journal-title":"World J Hepatol"},{"issue":"11","key":"4382_CR47","first-page":"e11488","volume":"12","author":"SA Hasan","year":"2020","unstructured":"Hasan SA, Haque A, Nazir F. Acute Limb Ischemia: A Rare Complication of COVID-19. Cureus. 2020;12(11):e11488.","journal-title":"Cureus"},{"key":"4382_CR48","unstructured":"Guidelines E. C.o.t.C.T.D.P.a.T. Chinese Guidelines for the Prevention and Treatment of Thrombotic Diseases[EB\/OL].15 October, 2018[https:\/\/www.medsci.cn\/guideline\/show_article.do?id=9c6711c0016ea294."},{"issue":"10","key":"4382_CR49","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1111\/jth.15808","volume":"20","author":"S Schulman","year":"2022","unstructured":"Schulman S, Sholzberg M, Spyropoulos AC, et al. ISTH guidelines for antithrombotic treatment in COVID-19. J Thromb Haemostasis: JTH. 2022;20(10):2214\u201325.","journal-title":"J Thromb Haemostasis: JTH"},{"issue":"10","key":"4382_CR50","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.1016\/j.jtha.2023.07.011","volume":"21","author":"R Giossi","year":"2023","unstructured":"Giossi R, Menichelli D, D\u2019Amico F, et al. Efficacy and safety of direct oral anticoagulants in the pediatric population: a systematic review and a meta-analysis. J Thromb Haemostasis: JTH. 2023;21(10):2784\u201396.","journal-title":"J Thromb Haemostasis: JTH"},{"key":"4382_CR51","first-page":"1195","volume-title":"Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions","author":"S Willmann","year":"2021","unstructured":"Willmann S, Coboeken K, Zhang Y, et al. Population pharmacokinetic analysis of rivaroxaban in children and comparison to prospective physiologically-based pharmacokinetic predictions. Volume 10. CPT: Pharmacometrics & Systems Pharmacology; 2021. pp. 1195\u2013207. 10."},{"key":"4382_CR52","first-page":"68","volume":"5","author":"A Mahajerin","year":"2017","unstructured":"Mahajerin A, Croteau SE. Epidemiology and Risk Assessment of Pediatric Venous Thromboembolism. Front Pead. 2017;5:68.","journal-title":"Front Pead"},{"issue":"9","key":"4382_CR53","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1016\/j.jtha.2023.05.014","volume":"21","author":"O Cohen","year":"2023","unstructured":"Cohen O, Efros O, Riva N, et al. Anticoagulant treatment for pediatric splanchnic vein thrombosis: a systematic review and meta-analysis. J Thromb Haemostasis: JTH. 2023;21(9):2499\u2013508.","journal-title":"J Thromb Haemostasis: JTH"},{"issue":"1","key":"4382_CR54","first-page":"2275912","volume":"28","author":"D Xie","year":"2023","unstructured":"Xie D, Xue X, Qiao W, et al. Thrombotic events and prophylactic anticoagulation in pediatric patients with COVID-19: a systematic review and meta-analysis. Hematol (Amsterdam Netherlands). 2023;28(1):2275912.","journal-title":"Hematol (Amsterdam Netherlands)"},{"issue":"6","key":"4382_CR55","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1182\/bloodadvances.2024014219","volume":"9","author":"DM Siegal","year":"2025","unstructured":"Siegal DM, Tseng EK, Sch\u00fcnemann HJ, et al. American Society of Hematology living guidelines on use of anticoagulation for thromboprophylaxis for patients with COVID-19: executive summary. Blood Adv. 2025;9(6):1247\u201360.","journal-title":"Blood Adv"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04382-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04382-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04382-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T03:19:11Z","timestamp":1783307951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04382-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":55,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4382"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04382-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written and verbal consent to write and publish this case report was obtained from the child himself and his parents. This was a retrospective study and was clinically ethical. This retrospective study was approved by the\n                      Medical Ethics Committee of the Children\u2019s Hospital of Soochow University\n                      (Approval\n                      No.2025CS032\n                      ). Every effort was made to minimize identifiable details of the case in order to maintain confidentiality and anonymity. Relevant clinical ethical guidelines and privacy protection regulations were strictly adhered to while conducting this study. Members of the treatment team received specialized training to ensure that the highest ethical standards were followed when handling sensitive information. In addition, all participants were scrutinized to ensure that they were qualified to participate in the study. During the writing of the report, we also paid special attention to the choice of wording and presentation to avoid any unnecessary distress or misunderstanding that might be caused to the child and his family. We believe that through these measures, we have not only protected the privacy of the participant, but also ensured the accuracy and reliability of the study results.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare they have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"239"}}